Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Voting Common Shares, no par value
-
Shares outstanding
-
51.9M
-
Number of holders
-
28
-
Total 13F shares, excl. options
-
6.7M
-
Shares change
-
+3.68M
-
Total reported value, excl. options
-
$28.3M
-
Value change
-
+$15.6M
-
Number of buys
-
22
-
Number of sells
-
-2
-
Price
-
$4.24
Significant Holders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) as of Q3 2020
29 filings reported holding DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value as of Q3 2020.
DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) has 28 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.7M shares
of 51.9M outstanding shares and own 12.91% of the company stock.
Largest 10 shareholders include Stonepine Capital Management, LLC (1.15M shares), Point72 Asset Management, L.P. (800K shares), Nantahala Capital Management, LLC (756K shares), Corriente Advisors, LLC (730K shares), Granite Point Capital Management, L.P. (647K shares), Manatuck Hill Partners, LLC (572K shares), Ikarian Capital, LLC (415K shares), Maven Securities LTD (359K shares), VANGUARD GROUP INC (342K shares), and CVI Holdings, LLC (276K shares).
This table shows the top 28 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.